An observational study in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Cardiovascular Disease (CVD) and Coronary Artery Calcification, sponsored by Watcharasak Chotiyaputta. Recruiting at 1 site in Thailand. Open to participants aged 35 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Watcharasak Chotiyaputta · Observational
Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in Thailand and is strongly linked to metabolic risk factors such as obesity, diabetes, hypertension, and dyslipidemia. Cardiovascular disease is the leading cause of death among patients with MASLD. Coronary artery calcium (CAC) scoring is a widely used marker of subclinical coronary atherosclerosis. This study aims to evaluate the association between cardiovascular risk assessment tools and CAC scores in Thai patients with MASLD to improve cardiovascular risk stratification in this population.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major public health concern in Thailand, with a high prevalence among individuals undergoing health evaluations. MASLD is closely associated with metabolic abnormalities and is recognized as an independent risk factor for cardiovascular disease (CVD). Although MASLD primarily affects the liver, multiple studies have shown that CVD is the leading cause of mortality in this population. Contributing mechanisms include insulin resistance, chronic low-grade inflammation, oxidative stress, and atherogenic dyslipidemia.
Coronary artery calcium (CAC) scoring, obtained through non-contrast cardiac CT, is a validated tool for detecting subclinical coronary atherosclerosis and predicting future cardiovascular events. Commonly used cardiovascular risk calculators-such as the Framingham Risk Score, ASCVD Risk Estimator, and UKPDS risk engine-were developed in Western populations and may not accurately reflect cardiovascular risk in Asian or Thai patients.
This observational study aims to investigate the relationship between cardiovascular risk assessment tools and CAC scores in Thai patients diagnosed with MASLD. Clinical data, metabolic parameters, liver disease severity, and CAC scores will be analyzed to determine how well existing risk calculators correlate with coronary calcification in this population. The findings may support improved cardiovascular risk stratification and help identify MASLD patients who may benefit from early cardiovascular evaluation.
4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.
This study's planned enrollment of 251 is below the median of 573 across 1,485 observational studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →This is the only study on the registry with Watcharasak Chotiyaputta as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Thai adults aged 35-75 years diagnosed with MASLD who underwent coronary artery calcium scoring at Siriraj Hospital. Clinical, metabolic, liver disease severity, and CAC score data are collected for cardiovascular risk analysis.
Exclusion Criteria:
Thai adult patients diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD) who underwent coronary artery calcium (CAC) scoring at Siriraj Hospital. Clinical, metabolic, liver disease severity, and CAC score data are collected to evaluate the association between cardiovascular risk assessment tools and coronary calcification.
Association between Thai CV Risk Score and Coronary Artery Calcium (CAC) Score in Thai MASLD patients
The study will evaluate the correlation between the Thai CV risk score and the coronary artery calcium (CAC) score in Thai patients diagnosed with MASLD. Clinical and metabolic parameters will be used to calculate ASCVD risk, and CAC scores will be obtained from non-contrast cardiac CT.
Time frame: Baseline
Plan to share: No — Individual participant data will not be shared due to patient privacy protection and institutional policy regarding clinical data from Siriraj Hospital.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.